Showing 7981-7990 of 8822 results for "".
- Thermi and Sinclair Terminate Collaboration on Silhouette Instalifthttps://practicaldermatology.com/news/thermi-and-sinclair-terminate-collaboration-on-silhouette-instalift/2457866/Thermi, an Almirall S.A. company, and Sinclair Pharma have mutually agreed to terminate their collaboration for the marketing of Silhouette Instalift. Both companies have been working through a join
- Meet the Newest AAD Officers and Board Membershttps://practicaldermatology.com/news/meet-the-newest-aad-officers-and-board-members/2457876/Suzanne M. Olbricht, MD, FAAD, a Boston-based dermatologist, will take the helm of the American Academy of Dermatology (AAD) as the new President. Her one-year term officially begins on Tuesday, Feb. 20, at the conclusion of the 2018 AAD Annual Meeting in San Diego. Dr. Olbricht is an ass
- Exciplex Phototherapy Device Debuts at AAD 2018https://practicaldermatology.com/news/exciplex-phototherapy-device-debuts-at-aad-2018/2457877/Excimer Therapies Inc., now has the exclusive U.S. distribution rights for the Clarteis SAS exciplex® phototherapy treatment device. Excimer Therapies officially enters the market and will demonstrate the exciplex during t
- Aqua Pharmaceuticals Supports Camp Discoveryhttps://practicaldermatology.com/news/aqua-pharmaceuticals-supports-camp-discovery/2457884/Aqua Pharmaceuticals, LLC is demonstrating its commitment to the dermatology community by supporting American Academy of Dermatology’s Camp Discovery and is making a donation up to $5,000 to support the camp
- Zylö Therapeutics: Adam Friedman, MD to Present Data at AAD Annual Meetinghttps://practicaldermatology.com/news/zyl-therapeutics-adam-friedman-md-to-present-data-at-aad-annual-meeting/2457886/Zylö Therapeutics, a nanotechnology-based biopharmaceutical company dedicated to bringing innovative technologies to multiple facets of medicine, announced that preclinical data, utilizing Zylö’s patented hydrogel-derived Na
- South Beach Symposium to Kick Off March 1https://practicaldermatology.com/news/south-beach-symposium-to-kick-off-march-1/2457895/Now celebrating its 16th year, the 2018 South Beach Symposium (SBS) will feature live demonstration workshops of minimally invasive aesthetic treatments with injectables and devices providing attendees with new skills and techniques th
- Bonti Takes Aim at Scar Reduction with Shine Clinical Programhttps://practicaldermatology.com/news/bonti-takes-aim-at-scar-reduction-with-shine-clinical-program/2457897/Bonti has begun their SHINE (Scar Healing Improvement with Neurotoxin E) clinical program, aimed at scar reduction using its novel neurotoxin. EB- 001 is a novel botulinum neurotoxin serotype E (BoNT/E) with a unique product profile, characterized
- Prestige Beauty Industry Grows to $17.7Bhttps://practicaldermatology.com/news/prestige-beauty-industry-grows-to-177b/2457900/The US prestige beauty industry reached $17.7 billion in 2017, a six percent increase over 2016, according to global information company The NPD Group. The skincare category led in growth with a nine percent increase in sales that contributed 45 percent of t
- SkylineDx and Mayo Clinic To Collaborate on Development of Diagnostic Tests for Melanomahttps://practicaldermatology.com/news/skylinedx-and-mayo-clinic-to-collaborate-on-development-of-diagnostic-tests-for-melanoma/2457903/SkylineDx and Mayo Clinic are working together to develop novel diagnostic tests which will improve clinical decision making for melanoma patients. SkylineDx will help Mayo Clinic to optimize and further develop an algorithm to identify risk factor
- Abeona Receives FDA Regenerative Medicine Advanced Therapy Designation for EB-101 Gene Therapy in EBhttps://practicaldermatology.com/news/abeona-receives-fda-regenerative-medicine-advanced-therapy-designation-for-eb-101-gene-therapy-in-eb/2457908/The US Food and Drug Administration (FDA) granted the Regenerative Medicine Advanced Therapy (RMAT) designation to EB-101, Abeona Therapeutics Inc.’s gene-corrected autologous cell therapy product for patients with recessive dystrophic epidermolysis bullosa (RDEB). “EB-101 is